Evidence Hub

Can patient-derived in vitro models improve clinical translation in critical care research when used before animal studies?

Alexandre Pierre, R. Favory, Steve Lancel, S. Préau

Intensive Care Medicine Experimental, 2025

7 citations

Abstract

Translational failure remains a major barrier in critical illness research, with preclinical findings from animal models often failing to replicate in human trials. Hypothesis: we hypothesize that the integration of advanced in vitro models derived from human cells—particularly those from ICU patients—prior to animal studies will enhance clinical translation in critical care research. These emerging human-relevant platforms—such as organ-on-chip microfluidic systems—recapitulate key aspects of human physiology and pathology that animal models often cannot, thereby avoiding interspecies differences, capturing patient-specific variability, and enabling the study of disease phenotypes and endotypes. We propose that advanced in vitro models should be used first to gain mechanistic insights and assess efficacy in a human-relevant setting, while subsequent animal studies would then serve to evaluate systemic effects and safety before translation to patients. By leveraging such complementary strengths, an integrated in vitro–in vivo pipeline could better bridge the bench-to-bedside gap. This approach aligns with 3Rs principles by refining and reducing animal use (screening therapeutics in human models to focus subsequent animal experiments), and potentially replacing certain animal tests pending rigorous validation and regulatory acceptance. Implementation will require regulatory support, as well as training and funding to overcome technical barriers. This hypothesis is testable…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free